AbCellera Signs a Multi-Target Collaboration with Angios to Develop Bispecific Antibodies for the Treatment of Diabetic Retinopathy

 AbCellera Signs a Multi-Target Collaboration with Angios to Develop Bispecific Antibodies for the Treatment of Diabetic Retinopathy

Shots:

  • AbCellera will receive equity and research fees and is eligible to receive milestone along with royalties based on the development and commercialization of Abs
  • Angios gets the rights to develop and commercialize therapeutic products resulting from the collaboration
  • AbCellera will use an AI-powered platform to generate panels of Abs for up to three Angios-selected targets against diabetic retinopathy

Click here to­ read full press release/ article | Ref: BUSINESS WIRE| Image: AbCellera

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post